Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Claim extract · Listening Library

Williams / Ferriss: magnesium–ibogaine for TBI/PTSD

LAST REVIEWED 2026-09-22 · MEDIA CLAIM EXTRACT · HIGH-CONFIDENCE LL ENTRY

Landmark Listening Library extract from Tim Ferriss Show #714 with Stanford psychiatrist Nolan Williams. Episode discussion is media; outcome claims track to the open-label Cherian et al. Nature Medicine paper and later methods critique — not to the podcast alone.

Media claim extract Observational / open-label Source-labeled

Listening Library source (outbound)

Entry: tim-ferriss-714-nolan-williams-2024 — “A Glimpse of the Future… and De-risking Ibogaine for TBI/PTSD” (The Tim Ferriss Show, 2024-01-05). Catalog confidence: high; needsVerify: false.

Listen outbound: tim.blog episode page (podcasts link out; IbogaBase does not host audio).

Related LL rows (same research window): ibogaine-uncovered-23-nolan-williams (clinic-adjacent host — commercial-proximity label); stanford-medicine-news-audio-adjacent (press framing risk).

Testable claims extracted (media → primary)

  1. Claim (media): Magnesium–ibogaine regimens used in special-operations veterans are associated with large improvements on TBI/PTSD symptom measures.
    Primary check: Cherian et al., “Magnesium–ibogaine therapy in veterans with traumatic brain injuries,” Nature Medicine 2024;30:373–381. PMID 38182784, DOI 10.1038/s41591-023-02705-w. Design: open-label / observational — not a confirmatory RCT.
  2. Claim (media): Cardiac / QT risk can be “de-risked” enough that research is ethically discussable.
    IbogaBase boundary: QT/QTc remains a standing safety theme — see Safety / QTc. Podcast reassurance is not a clearance protocol and IbogaBase gives no dosing or screening recipes.
  3. Claim (press / amplification risk): Institutional or influencer language that the Stanford work “proved” TBI/PTSD treatment.
    Counter-check: Gorman DM, 2026, Int J Drug Policy — registration non-adherence atop methodological weakness. PMID 42330793. Full card: Stanford Mg-ibogaine critique.

Verdict

Media / observational — not proven cure; not FDA-approved. Use the podcast to find the paper; grade the paper by design limits. Miracle or “proved TBI/PTSD” language outruns the evidence desk.

Open-label ≠ confirmatory Podcast ≠ primary source No miracle voice

Continue reading